GleamWall
中文EN

IRLA IRulya Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662774 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-87.4%
TTM EPS YoY193.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-98.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.6%
Debt / equity—
Current ratio14.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.44x
Accruals ratio-55.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.85M$5.46M$6.84M$12.60M$8.08M$6.55M$8.14M$5.83M
SG&A expense$9.02M$16.63M$4.27M$3.63M$3.28M$3.34M$4.79M$4.28M
Operating income-$13.14M-$79.78M-$14.59M-$19.35M-$13.43M-$10.43M-$14.86M-$12.01M
Pretax income——————-$14.98M—
Income tax-$302,000$75,000-$5.34M$3.15M-$46,000$67,000$47,000$7,000
Net income-$27.74M-$75.49M$35.91M-$39.46M-$13.44M-$16.05M-$15.03M-$12.46M
EBITDA-$13.13M-$79.74M-$14.55M-$19.31M-$13.39M-$10.39M-$14.83M-$12.00M
EPS (basic)-2.31-12.313.60—-49.83-68.75-3.42—
EPS (diluted)-2.31-12.312.88—-49.83-68.75-3.42—
Weighted avg. shares (diluted)12.00M6.13M9.19M—269,757233,4314.39M—
Balance sheet
Cash & equivalents$39.82M$115.98M$18.16M$5.81M$6.45M$16.83M$7.77M$6.21M
Short-term investments$65.42M$0$0$11.94M———$34.57M
Current assets$106.30M$123.41M$25.58M$22.90M$29.20M$37.34M$33.83M$44.04M
PP&E, net$69,000$506,000$550,000$595,000$616,000$573,000$448,000$315,000
Goodwill————$0——$0
Intangibles$0$0$0$67.82M$67.73M$67.57M$62.37M$60.05M
Total assets$106.47M$124.00M$26.62M$93.52M$109.90M$117.21M$107.09M$114.48M
Current liabilities$7.22M$8.50M$8.77M$43.23M$26.04M$7.47M$8.36M$7.28M
Short-term debt$0$0$0$18.03M$17.52M——$0
Long-term debt———$0$0$16.99M$15.27M$14.32M
Total debt———$18.03M$17.52M$16.99M$15.27M$14.32M
Total liabilities$28.37M$15.51M$10.95M$129.24M$108.84M$105.47M$88.51M$84.33M
Shareholders' equity-$65.70M-$35.32M$15.67M-$35.71M$1.06M$11.74M$18.58M$30.15M
Net debt———$12.22M$11.07M$163,000$7.50M$8.11M
Shares outstanding1.02M1.02M13.79M278,62754.49M53.62M44.09M44.00M
Cash flow statement
Operating cash flow-$9.84M-$18.89M-$7.63M-$10.48M-$9.93M-$11.41M-$9.60M-$7.55M
Capital expenditure$71,000$0$0$4,000$74,000$126,000$148,000$133,000
Free cash flow-$9.91M-$18.89M-$7.63M-$10.48M-$10.00M-$11.54M-$9.75M-$7.68M
Investing cash flow-$67.79M$8.00M$12.00M$8.07M-$1.78M$6.04M$10.90M$10.87M
Financing cash flow-$10,000$108.93M$9.44M$2.03M$1.38M$14.41M$87,000$0
Depreciation & amortization$15,000$41,000$36,000$39,000$36,000$35,000$32,000$16,000
Stock-based compensation$1.64M$12.09M$1.29M$1.19M$1.25M$1.27M$1.39M$1.12M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.